Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 3/20 | 0.32 |
| ▸ | F13A1 | P00488 | 2/20 | 0.32 |
| ▸ | TGM1 | P22735 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994716 | 1.00 | PREP (0.32) | PREPESR2TGM2F13A1TGM1 | |
| SCHEMBL1251172 | 0.82 | CHRM2 (0.33) | CHRM2CHRM1 | |
| SCHEMBL1251171 | 0.82 | CHRM2 (0.33) | CHRM2CHRM1 | |
| SCHEMBL994427 | 0.79 | STS (0.40) | NAMPTMAPK1SMN1; SMN2GPR119 | |
| SCHEMBL994410 | 0.79 | NR1H2 (0.32) | ESR2TGM2F13A1TGM1NR1H2 | |
| SCHEMBL994426 | 0.79 | STS (0.40) | NAMPTMAPK1SMN1; SMN2GPR119 | |
| SCHEMBL994409 | 0.79 | NR1H2 (0.32) | ESR2TGM2F13A1TGM1NR1H2 | |
| SCHEMBL27556840 | 0.74 | ESR2 (0.41) | ESR2TGM2F13A1TGM1NR1H2 | |
| SCHEMBL3867413 | 0.72 | ESR2 (0.38) | ESR2TGM2F13A1TGM1NR1H2 | |
| SCHEMBL10248518 | 0.72 | USP2 (0.40) | PREPESR2NR1H2MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-7612087-B2 | Therapy for bacteria infections | NOVEXEL (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7112592-B2 | topical bactericides and disinfectants for surgical instruments; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2006-09-26 | — | — | US | disclosed |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-08-24 | — | — | US | disclosed |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | PREP 42/4885ESR2 4493/4885TGM2 810/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | PREP 881/4885ESR2 4508/4885TGM2 1950/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | PREP 42/4885ESR2 4493/4885TGM2 810/4885 |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | PREP 881/4885ESR2 4508/4885TGM2 1950/4885 |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | BACE1, GAA, CEL | PREP 42/4885ESR2 4493/4885TGM2 810/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | PREP 881/4885ESR2 4508/4885TGM2 1950/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | PREP 42/4885ESR2 4493/4885TGM2 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.